Comparing Todos Medical (OTCMKTS:TOMDF) & Stevanato Group (NYSE:STVN)

Todos Medical (OTCMKTS:TOMDF) and Stevanato Group (NYSE:STVN) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, earnings, institutional ownership, valuation, dividends and risk.

Earnings & Valuation

This table compares Todos Medical and Stevanato Group”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Todos Medical	$12.23 million	0.02	-$43.31 million	N/A	N/A
Stevanato Group	$1.09 billion	4.94	$157.62 million	€0.47 ($0.49)	38.87

Stevanato Group has higher revenue and earnings than Todos Medical.

Analyst Recommendations

This is a summary of current recommendations for Todos Medical and Stevanato Group, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Todos Medical	0	0	0	0	0.00
Stevanato Group	0	1	3	0	2.75

Profitability

This table compares Todos Medical and Stevanato Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Todos Medical	N/A	N/A	N/A
Stevanato Group	10.47%	9.86%	5.79%

Risk and Volatility

Todos Medical has a beta of 0.06, meaning that its stock price is 94% less volatile than the S&P 500. Comparatively, Stevanato Group has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500.

Summary

Stevanato Group beats Todos Medical on 9 of the 9 factors compared between the two stocks.

About Todos Medical

Todos Medical Ltd., a vitro diagnostics company, develops and commercializes blood tests for the detection of cancer and Alzheimer disease in the United States. The company develops Total Biochemical Infrared Analysis, a proprietary cancer-screening technology using peripheral blood spectroscopy analysis for examination into cancer's influence on the immune system; Lymphocyte Proliferation Test, a diagnostic blood test that determines the ability of peripheral blood lymphocytes and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle; and blood tests for the detection of neurodegenerative disorders, such as Alzheimer's disease. Its cancer screening and diagnosis products include TM-B1 and TM-B2 for breast cancer tests; and TMC blood test for the screening and diagnosis of colon cancer. The company also offers Tollovid, a 3CL protease inhibitor dietary supplement to support healthy immune function against circulating coronaviruses; and Tollovir, an antiviral treatment for Covid-19 that is in Phase 2 clinical trial. Todos Medical Ltd. has a collaboration agreement with Integrated Health LLC, as well as has agreements with various companies to develop screening tests for SARS-nCoV-2; and to distribute certain COVID-19 test kits. Todos Medical Ltd. was incorporated in 2010 and is headquartered in Tel Aviv, Israel.

About Stevanato Group

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.